Therapeutically, the inhibition of SIRT1 to restore p65 K310 acetylation and reactivate the SASP may represent a promising strategy to trigger tumor-suppressive senescence and enhance the immune-mediated clearance of cancer cells [79]. This evidence concerns the gene SIRT1 and cancer.